Metabolic and Organoprotective Effects of Telmisartan in Patients with Essential Hypertension

Ye.P. Svishchenko, L.A. Mishchenko, L.S. Mkhitarian, I.N. Yevstratova, H.M. Bozhenko, V.V. Radchenko


The article presents data from a study of angiotensin II receptor blocker type 1 telmisartan effects on the status of carbohydrate and lipid metabolism, activity of low-grade systemic inflammation, structural parameters of left ventricle and renal function in patients with essential hypertension. The results showed a high antihypertensive efficacy of telmisartan: 73 % of patients achieved target blood pressure when using monotherapy, while in 37 % of patients blood pressure normalization occurred already in 2 weeks of treatment. Organoprotective properties of telmisartan combined with pronounced positive metabolic characteristics reliably prevent target organ damage and reduce the risk of cardiovascular accidents in patients with essential hypertension.


essential hypertension; metabolic effects; organoprotection; telmisartan


Рекомендації Української асоціації кардіологів з профілактики та лікування артеріальної гіпертензії / Є.П. Свіщенко, А.Е. Багрій, Л.М. Єна [та ін.]. — Київ, 2012. — 69 с.

Міщенко Л.А. Предиктори прогресування гіпертрофії лівого шлуночка у хворих на гіпертонічну хворобу / Л.А. Міщенко // Український кардіологічний журнал. — 2012. — № 3. — С. 15-21.

C-reactive protein and target organ damage in patients with primary hypertension / E. Ratto, G. Leoncini, F. Viazzi [et al.] // Am. J. Kidney Dis. — 2010. — Vol. 55 — P. 1050-1059.

Telmisartan, Ramipril, or both for patients of high risk of vascular events / S. Yusuf, P. Sleight, C. Anderson [et al.] // New Engl. J. Med. — 2008. — Vol. 358. — P. 1547-1559.

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial / S. Yusuf, K. Teo, C. Anderson [et al.]; for Telmisartan Randomised AssessmeNt Study in aCE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators // Lancet. — 2008. — Vol. 372. — P. 1174-1183.

Takagi H. Telmisartan improves insulin sensitivity: A meta-analisys of randomized head-to-head trials / H. Takagi, T. Umemoto // Int. J. Cardiol. — 2012. — Vol. 156. — P. 92-96.

Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials / B. Williams, Y. Lacourcie’re, H. Schumacher [et al.] // J. Hum. Hypertens. — 2009. — Vol. 23. — P. 610-619.

Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study / K. Kario, T.G. Pickering, Y. Umeda [et al.] // Circulation. — 2003. — Vol. 107. — P. 1401-1406.

Kario K. Morning surge and variability in blood pressure: a new therapeutic target? // Hypertension. — 2005. — Vol. 45. — P. 485-486.

Identification of telmisartan as an unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity / S.C. Benson, H.A. Pershadsingh, C.I. Ho [et al.] // Hypertension. — 2004. — Vol. 43. — P. 993-1002.

Effects of telmisartan on hypertensive patients with dyslipi-demia and insulin resistance / D. Xu, J. Liu, C. Ji [et al.] // J. Geriatr. Cardiol. — 2007. — Vol. 4. — P. 149-152.

Telmisartan as a metabolic sartan: the first meta-analisys of rando-mized control trials in metabolic syndrome / H. Takagi, M. Niva, Y. Mizuno [et al.] // J. Am. Society of hypertens. — 2013. — Vol. 7. — P. 229-235.

Vanitha M. Effect of telmisartan on serum lipid profile in patients with hypertension and dyslipidemia / M. Vanitha, K. Vijayal // Int. J. Med. Res. Health Sci. — 2013. — Vol. 2. — P. 745-749.

Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome / I. Porto, L. Di Vito, G.L. De Maria [et al.] // Am. J. Cardiol. — 2009. — Vol. 103. — P. 1500-1505.

Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus / S. Koulouris, P. Symeonides, K. Triantafyllou [et al.] // Am. J. Cardiol. — 2005. — Vol. 95. — P. 1386-1388.

Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis / Emerging Risk Factors Collaboration, S. Kaptoge, E. Di Angelantonio, G. Lowe // Lancet. — 2010. — Vol. 375. — P. 132-40.

Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study / D. Galzerano, P. Tammaro, A. Cerciell [et al.] // J. Hum. Hypertens. — 2004. — Vol. 18. — P. 53-59.

Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study / D. Galzerano, P. Tammaro, L. del Viscovo [et al.] // Am. J. Hypertens. — 2005. — Vol. 18. — P. 1563-1569.

Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the ongoing telmisartan alone and in combination with ramipril global end point trial and the telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease / P. Verdecchia, P. Sleight, G. Mancia [et al.]; for ONTARGET/TRANSCEND Investigators // Circulation. — 2009. — Vol. 120. — P. 1380-1389.

Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes / H. Makino, M. Haneda, T. Babazono [et al.]; for INNOVATION Study Group // Diabetes Care. — 2007. — Vol. 30. — P. 1577-1578.

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy / A.H. Barnett, S.C. Bain, P. Bouter [et al.]; for Diabetics Exposed to Telmisartan and Enalapril Study Group // N. Engl. J. Med. — 2004. — Vol. 351. — P. 1952-1961.

Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy / G. Bakris, E. Burgess, M. Weir [et al.]; for AMADEO Study Investigators // Kidney Int. — 2008. — Vol. 74. — P. 364-369.

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy / J. Galle, E. Schwedhelm, S. Pinnetti [et al.]; for VIVALDI investigators // Nephrol. Dial. Transplant. — 2008. — Vol. 23. — P. 3174-3183.

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial / J.F. Mann, R.E. Schmieder, M. McQueen [et al.]; for ONTARGET investigators // Lancet. — 2008. — Vol. 372. — P. 547-553.

The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial / L. Vogt, G. Navis, J. Kцster [et al.] for Angiotensin II Receptor Antagonist telmisartan Micardis in Isolated Systolic hypertension (ARAMIS) study group // J. Hypertens. — 2005. — Vol. 23. — P. 2055-2061.

Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта